 | |
- close
- close
|
Business Wire
Nov 25
Comment
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Company will present at the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2nd at 2:30 p.m. Eastern time (11:30 a.m. Pacific time) at the New York Palace
StreetInsider.com
Nov 24
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/AVANIR+Pharma+%28AVNR%29+Posts+Q4+Loss+of+9c%2C+Wider+than+Anticipated/5136428.html for the full story.
Business Wire
Nov 24
Comment
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today reported unaudited financial results for the three and twelve months ended September 30, 2009. For the fourth quarter of fiscal 2009, AVANIR reported a net loss from continuing operations of $7.0
Business Wire
Nov 17
Comment
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it will release unaudited financial results for the quarter and fiscal year ended September 30, 2009 before market open on Tuesday, November 24, 2009. Keith Katkin, President and Chief
Business Wire
Nov 11
Comment
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Company will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18th at 3:15 p.m. Eastern time (12:15 p.m. Pacific time) at the St. Regis
FierceBiotech
Nov 10
Comment
Shares of Avanir (AVNR) jumped almost 10 percent on the news that its low-dose version of Zenvia demonstrated a significant reduction in the number and severity of uncontrolled emotional outbursts among patients with multiple sclerosis and ALS...
Business Wire
Oct 20
Comment
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced that the Company will present at the BIOCOM Investor Conference on Monday, October 26th at 2:30 p.m. Eastern time (11:30 a.m. Pacific time) at the Hyatt Regency in La Jolla. The BIOCOM
Business Wire
Oct 13
Comment
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the
FierceBiotech
Oct 9
Comment
A Phase III trial of Avanir Pharmaceuticals' closely-watched drug Zenvia showed that the drug relieved Pseudobulbar affect (PBA) in a subset of multiple sclerosis patients, sending Avanir's stock up as much as 16 percent. PBA is a neurologic...
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
AVNR AT A GLANCE
References
| ||||||
|
|
